355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.
277 citations
,
December 2019 in “Frontiers in Immunology” This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.
223 citations
,
September 2018 in “Rheumatology” This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.
184 citations
,
February 2015 in “EBioMedicine” This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” In this review, the researchers reported that JAK inhibitors, originally approved by the FDA for other uses, have shown effectiveness in reversing hair loss in patients with moderate to severe alopecia areata, based on current preclinical and clinical studies.